Skip to content
DraconiticResearch
Search Sources API
197,768 studies31 sourcesUpdated 37 min ago
Peer-reviewedCC BYScience advances

Immune biomarkers of response and resistance to ipilimumab and nivolumab in metastatic castration-resistant prostate cancer

  • Apostolia M. Tsimberidou1
  • Christopher R. Cabanski2
  • Alexandra Drakaki3
  • Danny N. Khalil4
  • Bilal A. Siddiqui5
  • Sreyashi Basu6,7
  • Kwame Okrah2
  • Diane M. Da Silva2
  • Shikha Gautam2
  • Farah A. Alayli2
  • Mike Schachter2
  • Justin Fairchild2
6 more authors
  • Wai Chin Foo8
  • Silvia Boffo9
  • Jamie Arnott2
  • Ute Dugan2
  • Sumit K. Subudhi5
  • Padmanee Sharma5,6,7,10
10 affiliations
  1. 1Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  2. 2Parker Institute for Cancer Immunotherapy, San Francisco, CA, USA.
  3. 3University of California, Los Angeles Jonsson Comprehensive Cancer Center, Los Angeles, CA, USA.
  4. 4Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
  5. 5Department of Genitourinary Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  6. 6James P. Allison Institute, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  7. 7Immunotherapy Platform, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  8. 8Department of Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  9. 9Bristol Myers Squibb, New York, NY, USA.
  10. 10Department of Immunology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Read full textPDFDOICite

Related

  1. Neoadjuvant pepinemab in combination with nivolumab and/or ipilimumab in resectable metastatic melanoma: a pilot biomarker-driven trial
    Ayana T. Ruffin, Crystal L. Mallow, Brian M. Olson +24
    Nature CommunicationsPeer-reviewedCC BY 4.0Full textOncologyCrossref
  2. 484 Phase II neoadjuvant study of nivolumab alone and in combination with relatlimab or ipilimumab in resectable head and neck cancer
    Hong Wang, Lazar Vujanovic, Seungwon Kim +15
    Journal for ImmunoTherapy of CancerPeer-reviewedCC BYFull textOncologyDOAJ
  3. Peritoneal mesothelioma showing a remarkable response to nivolumab plus ipilimumab in a patient with Lynch syndrome: A case report and literature review
    Yuko Ueda, Rei Fukuda, Takayuki Ando +10
    Internal MedicinePeer-reviewedCC BY-NC-NDFull textSurgery & anaesthesiaJ-STAGE
  4. Marked Response to Nivolumab Plus Ipilimumab After the Failure of Two Prior Immune Checkpoint Inhibitor–Based Regimens Including CTLA-4 Blockade in Advanced Hepatocellular Carcinoma
    Shinichiro Minami, Wataru Sato, Kenjiro Yamamoto +7
    Internal MedicinePeer-reviewedCC BY-NC-NDFull text1 citedGeneral medicineJ-STAGE
  5. First-week expansion of activated peripheral B-cell subsets is associated with grade 3 or higher immune-related adverse events after nivolumab plus ipilimumab
    h. takakura, Y. Funakoshi, T. Koyama +10
    medRxivPreprintCC BYFull textGeneral medicinemedRxiv

Cite

BibTeXRIS
BibTeX
@article{tsimberidou2026immune,
  title = {{Immune biomarkers of response and resistance to ipilimumab and nivolumab in metastatic castration-resistant prostate cancer}},
  author = {Apostolia M. Tsimberidou and Christopher R. Cabanski and Alexandra Drakaki and Danny N. Khalil and Bilal A. Siddiqui and Sreyashi Basu and Kwame Okrah and Diane M. Da Silva and Shikha Gautam and Farah A. Alayli and Mike Schachter and Justin Fairchild and Wai Chin Foo and Silvia Boffo and Jamie Arnott and Ute Dugan and Sumit K. Subudhi and Padmanee Sharma},
  journal = {Science advances},
  year = {2026},
  month = oct,
  doi = {10.1126/sciadv.aee8730},
  url = {https://europepmc.org/article/PMC/PMC13666023},
  note = {CC BY},
}
RIS
TY  - JOUR
TI  - Immune biomarkers of response and resistance to ipilimumab and nivolumab in metastatic castration-resistant prostate cancer
AU  - Apostolia M. Tsimberidou
AU  - Christopher R. Cabanski
AU  - Alexandra Drakaki
AU  - Danny N. Khalil
AU  - Bilal A. Siddiqui
AU  - Sreyashi Basu
AU  - Kwame Okrah
AU  - Diane M. Da Silva
AU  - Shikha Gautam
AU  - Farah A. Alayli
AU  - Mike Schachter
AU  - Justin Fairchild
AU  - Wai Chin Foo
AU  - Silvia Boffo
AU  - Jamie Arnott
AU  - Ute Dugan
AU  - Sumit K. Subudhi
AU  - Padmanee Sharma
PY  - 2026
DA  - 2026/10/16
JO  - Science advances
DO  - 10.1126/sciadv.aee8730
UR  - https://europepmc.org/article/PMC/PMC13666023
SN  - 2375-2548
ER  -